Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1849 2
1850 3
1851 1
1852 2
1854 1
1864 1
1865 1
1867 2
1936 1
1941 1
1945 1
1946 1
1948 1
1949 1
1950 3
1951 6
1952 4
1953 1
1954 5
1955 2
1956 8
1957 8
1958 3
1959 1
1960 2
1961 4
1962 2
1963 3
1964 1
1965 5
1966 8
1967 11
1968 6
1969 14
1970 14
1971 16
1972 7
1973 15
1974 6
1975 7
1976 2
1977 6
1978 11
1979 7
1980 18
1981 15
1982 11
1983 27
1984 17
1985 24
1986 27
1987 23
1988 28
1989 28
1990 23
1991 36
1992 49
1993 54
1994 60
1995 69
1996 81
1997 73
1998 85
1999 94
2000 93
2001 91
2002 84
2003 100
2004 125
2005 124
2006 135
2007 141
2008 134
2009 154
2010 150
2011 179
2012 160
2013 159
2014 177
2015 217
2016 195
2017 194
2018 181
2019 269
2020 252
2021 245
2022 214
2023 218
2024 86

Text availability

Article attribute

Article type

Publication date

Search Results

4,682 results

Results by year

Filters applied: . Clear all
Page 1
Recent advances in immunotherapies for lupus nephritis.
Kaneko M, Jackson SW. Kaneko M, et al. Among authors: jackson sw. Pediatr Nephrol. 2023 Apr;38(4):1001-1012. doi: 10.1007/s00467-022-05670-7. Epub 2022 Jul 1. Pediatr Nephrol. 2023. PMID: 35778517 Free PMC article. Review.
Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model.
Fang TZ, Sun Y, Pearce AC, Eleuteri S, Kemp M, Luckhurst CA, Williams R, Mills R, Almond S, Burzynski L, Márkus NM, Lelliott CJ, Karp NA, Adams DJ, Jackson SP, Zhao JF, Ganley IG, Thompson PW, Balmus G, Simon DK. Fang TZ, et al. Among authors: jackson sp. Nat Commun. 2023 Nov 13;14(1):7295. doi: 10.1038/s41467-023-42876-1. Nat Commun. 2023. PMID: 37957154 Free PMC article.
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss BJ, Moreno C, Szafer-Glusman E, Russell K, Zhou C, Ninomoto J, Dean JP, Wierda WG, Ghia P. Tam CS, et al. Among authors: jackson s. Blood. 2022 Jun 2;139(22):3278-3289. doi: 10.1182/blood.2021014488. Blood. 2022. PMID: 35196370 Free PMC article.
Mindfulness for smoking cessation.
Jackson S, Brown J, Norris E, Livingstone-Banks J, Hayes E, Lindson N. Jackson S, et al. Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD013696. doi: 10.1002/14651858.CD013696.pub2. Cochrane Database Syst Rev. 2022. PMID: 35420700 Free PMC article. Review.
Spatially resolved isotope tracing reveals tissue metabolic activity.
Wang L, Xing X, Zeng X, Jackson SR, TeSlaa T, Al-Dalahmah O, Samarah LZ, Goodwin K, Yang L, McReynolds MR, Li X, Wolff JJ, Rabinowitz JD, Davidson SM. Wang L, et al. Among authors: jackson sr. Nat Methods. 2022 Feb;19(2):223-230. doi: 10.1038/s41592-021-01378-y. Epub 2022 Feb 7. Nat Methods. 2022. PMID: 35132243 Free PMC article.
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS. Wierda WG, et al. Among authors: jackson s. J Clin Oncol. 2021 Dec 1;39(34):3853-3865. doi: 10.1200/JCO.21.00807. Epub 2021 Oct 7. J Clin Oncol. 2021. PMID: 34618601 Free PMC article. Clinical Trial.
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, Paneesha S, Fox CP, Eyre TA, Forconi F, Elmusharaf N, Kennedy B, Gribben J, Pemberton N, Sheehy O, Preston G, Schuh A, Walewska R, Duley L, Howard D, Hockaday A, Jackson S, Greatorex N, Girvan S, Bell S, Brown JM, Webster N, Dalal S, de Tute R, Rawstron A, Patten PEM, Hillmen P; National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup. Munir T, et al. Among authors: jackson s. N Engl J Med. 2024 Jan 25;390(4):326-337. doi: 10.1056/NEJMoa2310063. Epub 2023 Dec 10. N Engl J Med. 2024. PMID: 38078508 Clinical Trial.
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Moreau P, et al. Among authors: jackson sr. N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282. N Engl J Med. 2016. PMID: 27119237 Free article. Clinical Trial.
4,682 results